Transgene
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Transgene sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Transgene: 7 sponsored US clinical trials, none currently recruiting.
Transgene sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HPV-Related Vulvar Squamous Cell Carcinoma, with 1 trials.
Upper-quartile sponsor footprint
Transgene sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
7 total, page 1 of 1
A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
NCT04183166
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
NCT03260023
A Trial Evaluating TG4050 in Ovarian Carcinoma.
NCT03839524
A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
NCT03353675
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
NCT01383148
Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma
NCT00394693
Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer
NCT00040170
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 4 |
How the Transgene early-phase archive is shaped
7 indexed studies, none listed as recruiting (0% open); 3 completed (43%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: HPV-Related Vulvar Squamous Cell Carcinoma (1 trial), 5 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Transgene: archived-pipeline peers nationwide
Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Transgene sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 archived trials
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Transgene page
7 registered trials is a research-attention snapshot, not an endorsement of Transgene or any single study.
- None of Transgene's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- HPV-Related Vulvar Squamous Cell Carcinoma is the condition Transgene studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HPV-Related Vulvar Squamous Cell Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Transgene pipeline card: 7 registered trials from official public datasets.Report a data error.